A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities
Latest Information Update: 05 May 2026
At a glance
- Drugs Ecnoglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Verdiva Bio
Most Recent Events
- 05 May 2026 New trial record